SeaStar Medical to Present at Noble Capital Markets' NobleCon20 on December 4, 2024
SeaStar Medical to Present at Noble Capital Markets' NobleCon20 on December 4, 2024
SeaStar Medical is a commercial-stage medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical's novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit or visit us on LinkedIn or X.DENVER, Nov. 26, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will present a company overview at NobleCon20, Noble Capital Markets' 20th Annual Emerging Growth Equity Conference, on Wednesday, December 4 at 12:00 p.m. Eastern time (9:00 a.m. Pacific time). The conference is being held in Boca Raton, Fla.
丹佛，2024年11月26日（環球新聞）-- SeaStar Medical Holding Corporation（納斯達克：ICU），一家商業階段的醫療器械公司，正在開發專有解決方案以減少超炎症對重要器官的影響，管理層宣佈將在NobleCon20上介紹公司資料，Noble Capital Markets第20屆年度新興增長股票會議，將於12月4日星期三東部時間下午12:00（太平洋時間上午9:00）進行。會議將在佛羅里達州博卡拉頓舉行。
A webcast of the presentation will be available beginning December 5 on the Company website and will be archived for 90 days.
演示的網絡廣播將於12月5日開始在公司網站上提供，並將存檔90天。
About SeaStar Medical
關於SeaStar Medical
SeaStar Medical is a commercial-stage medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical's novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit or visit us on LinkedIn or X.
SeaStar Medical是一家商業階段的醫療科技公司，正在重新定義體外治療如何減少過度炎症對重要器官的影響。SeaStar Medical的創新技術依賴於科學和創新，爲危重病患者提供救命解決方案。公司正在開發和商業化以細胞爲導向的體外療法，針對導致全身炎症的效應細胞，這些細胞會造成直接的組織損傷，並分泌一系列促炎症細胞因子，啓動並傳播失衡的免疫反應。欲了解更多信息，請訪問或在LinkedIn或X上關注我們。
Contact:
聯繫：
Alliance Advisors IR
Jody Cain
(310) 691-7100
Jcain@allianceadvisors.com
聯盟顧問投資者關係
喬迪·凱恩
(310) 691-7100
Jcain@allianceadvisors.com
# # #
# # #
譯文內容由第三人軟體翻譯。
